This is a preview of subscription content, log in via an institution to check access.
Notes
Treatment Options for Relapsed or Refractory Multiple Myeloma: Effectiveness, Value, and Value-based Price Benchmarks; see PharmacoEconomics & Outcomes News 753 p6; 803185191
Reference
Bristol Myers Squibb. How to Define Value: Patient Outcomes or Modeling? Internet Document : 26 May 2016. Available from: URL: http://news.bms.com/press-release/how-define-value-patient-outcomes-or-modeling-icer-multiple-myeloma
Rights and permissions
About this article
Cite this article
BMS "fundamentally disagree" with ICER's conclusions on elotuzumab. PharmacoEcon Outcomes News 754, 2 (2016). https://doi.org/10.1007/s40274-016-3072-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3072-7